when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Keytruda · news · pharmadog

← back to Keytruda

News mentioning Keytruda

114 stories

29dReplimune rebounds to win FDA approval of melanoma drugbiopharma dive

Aug 6, 26Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he wasstat

Aug 5, 26Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchbiopharma dive

Aug 5, 265 NextGen winners who went public this year (and which ones are hiring)biospace

Aug 4, 26Merck plans trial of sac-TMT combo with Keytruda in lung cancerendpoints

Aug 4, 26Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missbiospace

Aug 4, 26As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerbiospace

Aug 4, 26Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trialsfiercebiotech

Jul 30, 26Replimune melanoma drug wins support of FDA panelbiopharma dive

Jul 29, 26Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationfiercebiotech

Jul 28, 26FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcommbiospace

Jul 27, 26AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failurebiospace

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

Jul 23, 26Biopharma layoffs must double in H2 for 2026 to match 2025 cutsbiospace

Jul 22, 26Summit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 16, 26Merck wins first approval of a PCSK9 cholesterol pillbiopharma dive

Jul 15, 26Merck ADC, in China study, shows potential to replace chemo in lung cancerbiopharma dive

Jul 15, 26STAT+: Celcuity’s breast cancer drug approved, its firststat

Jul 15, 26Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytrudabiospace

Jul 14, 26STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last yearstat

Jul 13, 26Agenus surges on study pivot; Apnimed lines up an IPObiopharma dive

Jul 2, 26Roche KRAS drug succeeds in head-to-head lung cancer studybiopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 15, 26Medicare drug price rule may target under-the-skin Keytruda and Opdivobiopharma dive

Jun 12, 26Merck brings Welireg-Keytruda combo to treat kidney cancerendpoints

Jun 11, 26Summit pulls $500M share sale a day after announcing itbiopharma dive

Jun 9, 26Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesbiopharma dive

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

← prevpage 2 of 4next →